Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis

IMPORTANCE: The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars. OBJECTIVE: To assess the outcomes following a mandatory nonmedical s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Dermatol
Autori principali: Loft, Nikolai, Egeberg, Alexander, Rasmussen, Mads Kirchheiner, Bryld, Lars Erik, Nissen, Christoffer Valdemar, Dam, Tomas Norman, Ajgeiy, Kawa Khaled, Iversen, Lars, Skov, Lone
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2021
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027941/
https://ncbi.nlm.nih.gov/pubmed/33825804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2021.0221
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi